How Long Can You Live With a Pulmonary Embolism?

Survival after a pulmonary embolism ranges from minutes to decades, depending almost entirely on how large the clot is, how quickly treatment starts, and what other health conditions you have. Roughly a quarter of people with PE die suddenly as the first sign of the disease, while many others survive the initial event and go on to live for years with proper treatment. The spectrum is enormous, and understanding where you fall on it requires knowing how doctors classify PE severity and what that classification means for your body.

How a Pulmonary Embolism Threatens Your Life

A pulmonary embolism happens when a blood clot, usually formed in a deep vein in the leg, breaks loose and travels to the lungs. Once there, it blocks one or more pulmonary arteries. The immediate danger is not to the lung tissue itself but to the right side of your heart. Your right ventricle is built for low-pressure work, pumping blood through the normally low-resistance vessels of the lungs. When a clot suddenly blocks a large portion of that vascular bed, pulmonary pressure spikes and the right ventricle has to work dramatically harder.

This strain can cause the right ventricle to dilate and lose its ability to contract effectively, reducing cardiac output. A sharp rise in pulmonary pressure is typically seen when more than half of the pulmonary vasculature is obstructed. The failing right ventricle then bulges into the left ventricle, further reducing the heart’s ability to pump blood to the rest of the body. Low blood pressure, poor oxygen delivery, and abnormal heart rhythms can cascade into full hemodynamic collapse.

About 45% of people with acute PE develop some degree of right ventricular failure, though the severity varies widely. In the worst cases, this failure is the direct cause of death within hours or even minutes of the clot reaching the lungs.

Severity Is the Single Biggest Factor

Doctors classify PE into three broad categories: massive (also called high-risk), submassive (intermediate-risk), and low-risk. These categories drive almost every conversation about prognosis. In one long-term study, overall mortality rates across the entire follow-up period were about 71% for massive PE, roughly 45% for submassive PE, and around 28% for low-risk PE. The severity of the initial presentation predicted both short-term and long-term death.

⁴

Massive PE means you have dangerously low blood pressure or cardiac arrest at presentation. These patients face the highest immediate mortality rate, and many do not survive the first hours. Submassive PE is a trickier category: you are hemodynamically stable (your blood pressure is acceptable), but imaging or lab tests show the right ventricle is under significant strain. By definition, submassive PE carries a worse prognosis than standard low-risk PE, but the best treatment strategy for this middle group remains a matter of active debate because aggressive clot-dissolving drugs improve heart function but also increase the risk of dangerous bleeding.

⁵

Low-risk PE, by contrast, carries a much better prognosis. Many patients in this group can even be treated at home with blood thinners and monitored as outpatients.

Short-Term Survival Numbers

Most PE deaths happen early. Among elderly patients with confirmed PE in one study, mortality was about 14% within 30 days and roughly 21% within 90 days.

⁶ Those numbers reflect an older population, and younger, healthier patients tend to fare considerably better.

Doctors use scoring tools to estimate short-term risk more precisely. The Pulmonary Embolism Severity Index, or PESI, assigns points based on factors like age, heart rate, blood pressure, oxygen levels, and the presence of cancer or heart failure. In validation studies, patients classified as low-risk by a simplified version of this score had a 30-day mortality of about 1%, compared with roughly 9% to 11% in the high-risk group.

⁷ In another validation, there were no deaths in the three lowest PESI risk classes, while the highest risk class had a 30-day mortality over 9% and a 90-day mortality above 10%.⁸

The practical takeaway: if your PE is classified as low-risk and you have no major comorbidities, your chance of surviving the first month is very high. If your PE is massive or you are elderly with significant other illnesses, the short-term danger is real and substantial.

Cancer Changes Everything

Cancer is probably the single most important comorbidity when it comes to PE prognosis. PE associated with cancer carries a four- to seven-fold increased risk of death compared with PE in people without cancer.

⁹ The reasons are layered: cancer itself increases the blood’s tendency to clot, many cancer treatments further raise clotting risk, and the underlying malignancy contributes its own mortality independent of the PE.

One study found that the one-year survival probability for patients with cancer-associated PE was about 60%, and the five-year survival probability was roughly 39%. Both short-term and long-term survival were significantly worse compared with people whose PE was not linked to cancer, across all age groups.

¹⁰

Recurrence is another problem. After cancer patients stop anticoagulation, the cumulative rate of another blood-clot event is about 28% at one year and roughly 35% at five years. This is substantially higher than recurrence rates in patients without cancer and helps explain why many oncologists recommend continuing blood thinners indefinitely as long as cancer is active.

¹¹

How Treatment Shapes Long-Term Survival

Anticoagulation, or blood-thinning therapy, is the backbone of PE treatment. It does not dissolve the existing clot but prevents new ones from forming while your body gradually breaks down what is already there. How long you stay on anticoagulants depends on the circumstances. A PE triggered by a temporary risk factor like surgery or a long flight might warrant only three to six months of treatment. An unprovoked PE or one linked to an ongoing risk factor may require indefinite therapy.

Extended anticoagulation clearly reduces recurrence. In one large observational study, the combined rate of death or recurrent clot events was about 2% in patients who continued anticoagulants, compared with roughly 8% in those who stopped.

¹² However, a meta-analysis of randomized trials found that extended anticoagulation did not clearly reduce overall mortality when all drug types were pooled together, though it did roughly double the risk of major bleeding.¹³

The type of blood thinner matters. Newer direct oral anticoagulants showed a significant mortality reduction compared with placebo in that same meta-analysis, without the increased bleeding risk seen with older warfarin-type drugs. Across broader studies comparing the two drug classes directly, newer agents were linked to lower rates of fatal bleeding, cardiovascular death, and death from any cause.

¹⁴

When Clot-Busting Procedures Are Needed

For massive or high-risk PE, anticoagulation alone may not be enough. These patients sometimes need reperfusion therapy to physically remove or dissolve the clot. The two main options are systemic thrombolysis (a powerful clot-dissolving drug given through an IV) and catheter-directed thrombolysis (delivering the drug directly into the clot through a catheter threaded into the pulmonary artery).

Catheter-directed approaches have gained traction in recent years. A meta-analysis found that for high-risk PE, catheter-directed thrombolysis had a clinical success rate above 80% and a 30-day mortality of about 8%, though bleeding remained a real concern.

¹⁵ A nationwide population-based study found that patients who received catheter-directed therapy had lower in-hospital mortality than those who received systemic thrombolysis (about 13% versus 21%), as well as lower one-year death rates and fewer recurrent PEs. Bleeding risk was similar between the two approaches.¹⁶

These procedures are not without danger. But for people in hemodynamic collapse, the alternative of anticoagulation alone carries higher mortality. The choice is a calculated trade-off, and the development of specialized PE response teams at many hospitals has helped standardize how those decisions get made.

Provoked Versus Unprovoked PE

You might assume that a PE with a clear trigger, like a recent surgery, immobilization, or pregnancy, would behave differently from one that appears out of nowhere. Somewhat surprisingly, short-term outcomes for these two groups are not as different as you’d expect. In the large international GARFIELD-VTE registry, one-year death rates were comparable between patients with temporary provoking factors and those with unprovoked PE, at roughly 4 and 3 per 100 person-years respectively. Recurrence rates were similarly close.

¹⁷

The real difference between these groups shows up in long-term recurrence risk after anticoagulation stops. If your PE was provoked by a one-time event that has resolved, your risk of another clot is relatively low once you complete your course of treatment. If no clear trigger is ever identified, the recurrence risk is higher, which is why doctors often recommend longer or indefinite anticoagulation for unprovoked events. The decision is not about how bad the first PE was, but about whether the underlying tendency to form clots is ongoing.

Diagnostic Delay and Why Hours Matter

PE is notoriously tricky to diagnose. Its symptoms, including shortness of breath, chest pain, and a fast heart rate, overlap with a long list of other conditions. That ambiguity costs lives. In one study, patients whose diagnosis was delayed had a significantly worse 30-day outcome: about 6% experienced a serious event compared with roughly 3% among those diagnosed promptly.

¹⁸

The urgency is not just about diagnosis but about treatment speed. Among patients with high-risk PE, survivors received their first dose of anticoagulation a median of about 3.6 hours after arriving at the hospital, while non-survivors waited a median of nearly 6 hours.

¹⁹ A two-hour difference in a chaotic emergency department may sound small, but in the setting of a failing right ventricle, it can be the difference between recovery and death.

When PE Is Found by Accident

Not all pulmonary embolisms announce themselves. A growing number are discovered incidentally, usually when a CT scan is done for something else entirely, like staging a cancer or evaluating an infection. These silent PEs are more common than many people realize; in studies of patients with deep vein thrombosis who were systematically scanned, about a third had silent clots in their lungs.

²⁰

The encouraging news is that asymptomatic PE does not appear to carry the same recurrence risk as symptomatic disease. In long-term follow-up studies, silent PE was not significantly associated with higher rates of future clot events.²¹ That said, most clinicians still treat incidental PE with anticoagulation, particularly in cancer patients, because the underlying clotting tendency remains and the stakes of a recurrence are high. What drives recurrence risk in these cases is not the silent PE itself but the reason it happened, such as whether the original deep vein thrombosis was provoked or unprovoked and whether D-dimer levels remain elevated after treatment stops.

²⁰

Life After PE and Chronic Complications

Surviving the acute event is only part of the story. Among PE survivors, roughly half report persistent shortness of breath, reduced ability to exercise, and a lower quality of life in the months and years that follow.

²² This cluster of lingering symptoms is often called post-PE syndrome. A meta-analysis found that about a third of PE survivors had at least mild functional impairment, and about 11% had moderate-to-severe limitations in their daily activities.

²³

The most feared chronic complication is chronic thromboembolic pulmonary hypertension, or CTEPH, which develops in up to about 4% of PE survivors. In CTEPH, organized scar tissue from the original clot permanently narrows the pulmonary arteries, creating sustained high pressure that slowly wears down the right ventricle. Left untreated, the prognosis is grim. In an international registry, three-year survival for CTEPH patients who did not undergo surgery was only about 70%.

²⁴

Surgery to remove the scar tissue, called pulmonary endarterectomy, dramatically changes the trajectory. In the same registry, three-year survival for operated patients was about 89%. A Swedish study following patients for 15 years after this surgery found that those who survived the operation and early recovery period had a life expectancy only slightly shorter than the general population.

²⁵

Age, Sex, and Demographic Patterns

Age is a consistent and powerful predictor of PE mortality. In studies of elderly patients with venous clot events, each additional decade of age increased the risk of death by about 32%.

²⁶ Low physical activity level before the PE also nearly doubled the long-term death risk in that same cohort, suggesting that baseline fitness and frailty matter enormously in older adults.

Sex differences in PE are more nuanced than a simple “men do worse” or “women do worse” framing. Women and men get PE at similar overall rates, but the timing differs: women have higher rates in early and mid-adulthood, while men are more frequently affected after age 60. Women diagnosed with PE are more likely to present with severe features like low blood pressure and right ventricular dysfunction, yet they are less likely to receive aggressive treatments like thrombolysis. Women also experience more bleeding complications from all types of anticoagulation.

²⁷

Racial disparities are stark. Analysis of decades of U.S. mortality data shows that Black adults have had a PE death rate roughly twice that of White adults. Looking forward, forecasts project overall PE mortality will continue to decline through 2040, though the highest predicted rates remain among adults over 65.

³ The overall trend is encouraging: PE death rates have been falling for decades thanks to better diagnostic imaging, faster treatment protocols, and newer anticoagulants. But those improvements have not reached all groups equally, and age remains the single factor no treatment can fully overcome.